HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.

doi:10.1111/apt.15563

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.

Alimentary pharmacology & therapeutics - 1 Feb 2020

Wilson Aze, Peel Celeste, Wang Qian, Pananos Athanasios Demetri, Kim Richard B

Abstract excerpt

BACKGROUND: Anti-drug antibodies (ADAs) are a leading contributor to infliximab loss of response and adverse drug events. It is not feasible to identify patients at risk of antibody formation before initiating infliximab. The genetic variation HLADQA1*05 (rs2097432) has been linked to infliximab antibody formation in Crohn's disease (CD). AIMS: To evaluate the association between HLADQA1*05 and infliximab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antibody Formation

Share to Drug-Related Side Effects and Adverse Reactions

Share to Drug Resistance

Share to HLA-DQ alpha-Chains

Share to Inflammatory Bowel Diseases

Share to Infliximab

Share to Pharmacogenomic Testing

Source

Open in PubMed

Identifiers

PMID: 31650614
DOI: 10.1111/apt.15563

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.PMID 31650614Read ↗

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity Read ↗

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.Semantic proximity Read ↗

HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patientsSemantic proximity Read ↗

Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1∗05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease.Semantic proximity Read ↗

Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.Semantic proximity Read ↗

Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD PatientsSemantic proximity Read ↗

Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.Semantic proximity Read ↗

HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.Semantic proximity Read ↗

Decreased Infliximab Concentrations in Patients With Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or Variant HLADQA1*05G>A Genotype.Semantic proximity Read ↗

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabSemantic proximity Read ↗

Identification of HLA-DRB1 association to adalimumab immunogenicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.